An­nex­on lays out more GA drug da­ta; Okyo Phar­ma pulls back pub­lic of­fer­ing

In May, An­nex­on’s drug can­di­date ANX007 did not prove bet­ter at re­duc­ing the le­sion growth in a lead­ing cause of blind­ness. Now more da­ta have been un­veiled as to what had ini­tial­ly hap­pened.

An­nex­on is tout­ing that the drug of­fered pro­tec­tion from vi­sion loss and shown in ad­di­tion­al mea­sures of vi­su­al func­tion, such as low lu­mi­nance vi­su­al ac­tiv­i­ty and low lu­mi­nance vi­su­al deficit. An­nex­on said it has al­so done more analy­ses on the tri­al and pre­sent­ed that the can­di­date showed risk re­duc­tion for the best cor­rect­ed vi­su­al acu­ity mar­ket in GA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER